

Journal Club Spotlights: Current Advancements in Non-Small Cell Lung Cancer



Key Concepts

LIBRETTO-432 Trial

- Selpercatinib, a highly selective *RET* fusion inhibitor, demonstrates robust clinical efficacy (event-free survival and disease recurrence rates) compared to placebo in patients with early-stage *RET* fusion-positive NSCLC who had received definitive therapy for curative intent (surgery, radiotherapy, and adjuvant systemic anticancer therapy as appropriate).
- Appropriate awareness, education, and monitoring/management strategies, including prophylactic use of antidiarrheal agents and initiating antihypertensive therapy as necessary, are vital to effective management and maintaining patients on therapy.
- Patients with stage IB, II, or III NSCLC with a *RET* fusion mutation should be treated for 3 years with selpercatinib after definitive therapy, with or without chemotherapy.